Biomarkers in malignant pleural mesothelioma: current status and future directions

Ahmadzada, Tamkin; Reid, Glen; Kao, Steven

doi:10.21037/jtd.2018.04.31

Cited by 18 publications

(15 citation statements)

References 25 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Especially of interest are biomarkers in malignant pleural mesothelioma because of its late onset and long asymptomatic course. [80,81]. Numerous biomarkers have been reported to show promise, including osteopontin, fibulin-3, soluble mesothelin-related proteins, high mobility group box 1, micro-RNA’s, etc.…”

Section: Discussionmentioning

confidence: 99%

Malignant Pleural Effusion and Its Current Management: A Review

et al. 2019

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease. It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent. Additionally, the process of pathogenesis is greatly affected by activating mutations of EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK and RET, which correlate with an increased incidence of MPE. Considering all these changes, the authors aim to present a literature review of the newest findings, review of the guidelines and pathophysiological novelties in this field. Review of the just recently, after seven years published, practice guidelines, as well as analysis of more than 70 articles from the Pubmed, Medline databases that were almost exclusively published in indexed journals in the last few years, have relevance and contribute to the better understanding of the presented topic. MPE still presents a severe medical condition in patients with advanced malignancy. Recent findings in the field of pathophysiological mechanisms of MPE emphasize the role of molecular factors and mutations in the dynamics of the disease and its prognosis. Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. The current guidelines address multiple areas of interest bring novelties in the form of validated prediction tools and can, based on evidence, improve patient outcomes. However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant Pleural Effusion and Its Current Management: A Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Sarcomatoid MPMs, on the other hand, exhibit spindle cell morphology similar to sarcomas, are usually present with a pleural mass, and have the worst outcomes. Finally, biphasic or mixed MPMs have both epithelioid and sarcomatoid features [ 11 , 12 ]. The prognosis of MPM is generally poor, with a reported median overall survival of approximately one year after diagnosis, and there is no definitive cure for the disease [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…Finally, biphasic or mixed MPMs have both epithelioid and sarcomatoid features [ 11 , 12 ]. The prognosis of MPM is generally poor, with a reported median overall survival of approximately one year after diagnosis, and there is no definitive cure for the disease [ 12 ]. Despite the recent developments in medical oncology, MPM is refractory to currently available multimodal therapeutic options such as chemotherapy, radiation, and surgical resection [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Genomics and Functional Genomics of Malignant Pleural Mesothelioma

Çakıroğlu

Şentürk

2020

IJMS

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. The etiology of MPM is strongly associated with prior exposure to asbestos fibers, and the median survival rate of the diagnosed patients is approximately one year. Despite the latest advancements in surgical techniques and systemic therapies, currently available treatment modalities of MPM fail to provide long-term survival. The increasing incidence of MPM highlights the need for finding effective treatments. Targeted therapies offer personalized treatments in many cancers. However, targeted therapy in MPM is not recommended by clinical guidelines mainly because of poor target definition. A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes of MPM is required to identify novel targets and develop precise and effective treatments. Recent advances in the genomics and functional genomics fields have provided groundbreaking insights into the genomic and molecular profiles of MPM and enabled the functional characterization of the genetic alterations. This review provides a comprehensive overview of the relevant literature and highlights the potential of state-of-the-art genomics and functional genomics research to facilitate the development of novel diagnostics and therapeutic modalities in MPM.

show abstract

“…Notably, Jones et al presented a case with an exceptional and sustained response to immune checkpoint inhibition [5]. In order to finally reduce mortality there is a need to identify and validate appropriate biomarkers for the early detection of cancer, particularly for mesothelioma [6].…”

Section: Introductionmentioning

confidence: 99%

Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case–control study

et al. 2019

View full text Add to dashboard Cite

ObjectiveMalignant mesothelioma is an aggressive cancer of the serous membranes. For the detection of the tumor at early stages non- or minimally-invasive biomarkers are needed. The circulating biomarkers miR-132-3p, miR-126-3p, and miR-103a-3p were analyzed in a nested case–control study using plasma samples from 17 prediagnostic mesothelioma cases and 34 matched asbestos-exposed controls without a malignant disease.ResultsUsing prediagnostic plasma samples collected in median 8.9 months prior the clinical diagnosis miR-132-3p, miR-126-3p, and miR-103a-3p revealed 0% sensitivity on a defined specificity of 98%. Thus, the analyzed miRNAs failed to detect the cancer in prediagnostic samples, showing that they are not feasible for the early detection of malignant mesothelioma. However, the miRNAs might still serve as possible markers for prognosis and response to therapy, but this needs to be analyzed in appropriate studies.Electronic supplementary materialThe online version of this article (10.1186/s13104-019-4113-7) contains supplementary material, which is available to authorized users.

show abstract

Biomarkers in malignant pleural mesothelioma: current status and future directions

Cited by 18 publications

References 25 publications

Malignant Pleural Effusion and Its Current Management: A Review

Malignant Pleural Effusion and Its Current Management: A Review

Genomics and Functional Genomics of Malignant Pleural Mesothelioma

Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case–control study

Contact Info

Product

Resources

About